Skip to main content
. 2012 Mar;180(3):1179–1188. doi: 10.1016/j.ajpath.2011.11.026

Figure 6.

Figure 6

Expression of GLUT1 in low-grade ovarian serous tumors and the correlation of GLUT1 immunoreactivity with mutation status of BRAF and KRAS. Immunohistochemistry was performed in 33 cases of low-grade ovarian serous tumors including 23 serous borderline tumors and 10 advanced stage low-grade serous carcinomas. A: The GLUT1 immunostaining intensity is shown for all cases, which are grouped into BRAF mutation, KRAS mutation, and wild-type groups. Mutations of KRAS and BRAF are mutually exclusive. Low-grade serous carcinomas are labeled with asterisks, otherwise they are serous borderline tumors. B: Representative photomicrographs of low-grade serous carcinomas from each group are illustrated, and their mutation status in KRAS and BRAF is indicated below. The case numbers correspond to those shown above.